Griessbach, Alexandra; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Epp, Selina; Amstutz, Alain; Schönenberger, Christof M; ... (2023). Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2). Open Forum Infectious Diseases, 10(4), ofad150. Oxford University Press 10.1093/ofid/ofad150
|
Text
ofad150.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (405kB) | Preview |
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Eichenberger, Anna, Rauch, Andri |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2328-8957 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
11 Apr 2023 10:09 |
Last Modified: |
08 Jan 2024 12:55 |
Publisher DOI: |
10.1093/ofid/ofad150 |
PubMed ID: |
37035486 |
Additional Information: |
Annalisa Berzigotti, Guido Stirnimann, Guido Beldi und Vanessa Banz are members of the Swiss Transplant Cohort Study |
Uncontrolled Keywords: |
HIV Organ transplant SARS-CoV-2 Vaccine randomized trial |
BORIS DOI: |
10.48350/181617 |
URI: |
https://boris.unibe.ch/id/eprint/181617 |
Actions (login required)
 |
Edit item |